Haleon plc (HLNCF) Stock Price & Analysis
Haleon plc (HLNCF) — price $4.38 (-1.91%), as of the Oct 5, 2026 trading session; market cap $38.5B. Expected results Mar 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Haleon plc · HLNCF · Healthcare · Drug Manufacturers - Specialty & Generic
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products.
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.38 | |
| Change on the day | -1.91% | |
| 52-week range | $4.15 – $5.75 | |
| Market capitalisation | $38.5B | |
| Price / earnings (trailing) | 18.10 | |
| Shares traded on the day | 5.6K | |
| Beta (volatility vs the S&P 500) | 0.24 | |
| Dividends per share (last 12 months) | $0.10 | |
| Dividend yield (last 12 months) | 2.21% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Listen, in the second half, we expect a step-up in investment in growth, and that will show up in A&P.
Brian McNamara · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Haleon (HLNCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 2, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the HLNCF film — every key number, told as a short cinematic story
~2 min · open the film
What is Haleon (HLNCF), and what does it report?
Short answer · as of
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: Building 5, First Floor, THE Heights, Weybridge, X0, KT13 0NY. It employs 24,561 people and is led by Brian James McNamara. In Q2 FY2025 it reported revenue of $3.62B and net income of $533M. The market values it at $38.5B.
What do the latest results show for Haleon (HLNCF)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of $3.62B. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $7.43B Jul 30, 2026
- Latest report · revenue estimate
- $7.41B Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $7.43B | $7.41B | $0.1365 | $0.1326 |
| Feb 25, 2026 | $7.48B | $7.58B | $0.1293 | $0.1257 |
| Jul 31, 2025 | $7.52B | $7.58B | $0.1263 | $0.1237 |
| May 8, 2025 | $3.54B | $6.46B | $0.0576 | $0.1118 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | $3.62B | $533M | $0.06 (diluted) |
| Q1 FY2025 | $3.62B | $533M | $0.06 (diluted) |
| Q4 FY2024 | $3.65B | $305M | $0.03 (diluted) |
| Q3 FY2024 | $3.67B | $641M | $0.07 (diluted) |
What are the financial strengths and risks for Haleon (HLNCF)?
Short answer
The distress and quality screens read Altman Z 2.86 · Piotroski F 7. Trailing ratios: ROE 9.9% · ROA 5.0% · current ratio 0.69 · earnings yield 4.9% · free-cash-flow yield 3.6%.
What should you watch next at Haleon (HLNCF)?
Short answer · as of
The next earnings report is expected on Mar 4, 2027. The number it tests is the $0.21 EPS analysts carry for it. Analyst estimates on file carry FY2026 revenue $11.34B · EPS 0.21 · 16 analysts.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Listen, in the second half, we expect a step-up in investment in growth, and that will show up in A&P.
Brian McNamara ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q2 FY2025) was filed Jun 30, 2025 — 8 months ago.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $11.34B
- EPS estimate
- $0.21
Measured against a quoted price of $4.38 (as of Oct 5, 2026).
What has been published about Haleon (HLNCF)?
What Investors Ask About Haleon (HLNCF) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Haleon appear under drug manufacturers when it owns Sensodyne and Centrum?
The classification groups Haleon with specialty and generic drug producers, but its operating description is that of a global consumer healthcare company. Sensodyne, Centrum, Panadol, and its related brands generate sales through consumer health categories supported by production, distribution, and marketing.
How do Panadol, Voltaren, and Advil fit Haleon’s model?
They anchor Haleon’s pain-management offering within a broader portfolio that also covers oral health, respiratory care, digestive health, and supplements. Their role is to turn Haleon’s research, manufacturing, distribution, and promotional capabilities into repeat consumer demand across markets.
What is the HLNCF stock price today?
The last price recorded on this page for Haleon plc (HLNCF) is $4.38, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does HLNCF pay a dividend?
Yes. Haleon plc (HLNCF) shows a trailing 12-month dividend yield of 2.21%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (45 figures)
The 45 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Brian McNamara (Jul 30, 2026): Listen, in the second half, we expect a step-up in investment in growth, and that will show up in A&P. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Building 5, First Floor, THE Heights, Weybridge, X0, KT13 0NY | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "The Heights, Weybridge, SU, KT13 0NY, GB". |
FMP — 31 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $4.38 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:45.722Z. | |
px.change | Change on the day | -1.91% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $38.5B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T19:34:07.000Z. Captured from FMP at 2026-10-05T21:44:44.756Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Mar 4, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.085 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 18.10 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5.6K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.24 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers Specialty & Generic | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2844 — Perfumes, Cosmetics & Other Toilet Preparations. | |
id.employees | Employees | 24,561 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Brian James McNamara | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2025 | $3.62B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2025 | $533M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $7.43B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $7.41B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | $0.1365 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | $0.1326 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.revenue_actual | Revenue · reported — report date 2026-02-25 | $7.48B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.revenue_estimated | Revenue · estimate — report date 2026-02-25 | $7.58B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.eps_actual | EPS · reported — report date 2026-02-25 | $0.1293 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.eps_estimated | EPS · estimate — report date 2026-02-25 | $0.1257 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.revenue_actual | Revenue · reported — report date 2025-07-31 | $7.52B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.revenue_estimated | Revenue · estimate — report date 2025-07-31 | $7.58B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.eps_actual | EPS · reported — report date 2025-07-31 | $0.1263 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.eps_estimated | EPS · estimate — report date 2025-07-31 | $0.1237 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-08.revenue_actual | Revenue · reported — report date 2025-05-08 | $3.54B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-08.revenue_estimated | Revenue · estimate — report date 2025-05-08 | $6.46B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-08.eps_actual | EPS · reported — report date 2025-05-08 | $0.0576 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-08.eps_estimated | EPS · estimate — report date 2025-05-08 | $0.1118 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 7 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $4.15 – $5.75 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-05 | |
fin.scores | Distress and quality screens | Altman Z 2.86 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 9.9% · ROA 5.0% · current ratio 0.69 · earnings yield 4.9% · free-cash-flow yield 3.6% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.est_eps | EPS estimate, FY2026 | $0.21 | UNRECORDED | Stored analyst estimates — Captured 2026-10-05 | |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $11.34B · EPS 0.21 · 16 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-05 | |
earn.est_revenue | Revenue estimate, FY2026 | $11.34B | UNRECORDED | Stored analyst estimates — Captured 2026-10-05 |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.10 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.21% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($7.43B) with the recorded estimate ($7.41B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1365) with the recorded estimate ($0.1326) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-02-25.revenue_actual,earn.history.depth.2026-02-25.revenue_estimated,earn.history.depth.2026-02-25.eps_actual,earn.history.depth.2026-02-25.eps_estimated,earn.history.depth.2025-07-31.revenue_actual,earn.history.depth.2025-07-31.revenue_estimated,earn.history.depth.2025-07-31.eps_actual,earn.history.depth.2025-07-31.eps_estimated,earn.history.depth.2025-05-08.revenue_actual,earn.history.depth.2025-05-08.revenue_estimated,earn.history.depth.2025-05-08.eps_actual,earn.history.depth.2025-05-08.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - Specialty & Generic The company's SEC filings classify it under SIC 2844 — Perfumes, Cosmetics & Other Toilet Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Management outlook — dated call excerpts | Captured record · 1 entry
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-30 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
Data provided for informational purposes only.